Hotaling Investment Management’s United Therapeutics UTHR Stock Holding History

Hotaling Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$213K	Buy	+766	New	+$193K	0.1%	111

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hotaling Investment Management's UTHR Position: Q4 2022 in Review

Hotaling Investment Management opened a new position in United Therapeutics (UTHR) in Q4 2022: 766 shares worth $213K. The stake represents 0.1% of the portfolio and ranks #111 among its holdings.

512 funds tracked by Wall St. Rank hold UTHR as of Q4 2022.

Hotaling Investment Management held 766 shares of United Therapeutics worth $213K as of Q4 2022.
United Therapeutics was a new Hotaling Investment Management position in Q4 2022.
United Therapeutics made up 0.1% of Hotaling Investment Management's portfolio in Q4 2022, its #111 holding.
512 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2022.

Based on Hotaling Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.